Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold
Ask for high quality link by putting your email below
Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.
Many skin diseases, including psoriasis and basal cell carcinoma, are associated with microbial dysbiosis characterized by reduced C. acnes prevalence. C. acnes is a facultative anaerobic bacterium that is frequently found on the human skin. Read more…
The California Cruelty-Free Cosmetics Act, SB 1249, was introduced in the California State Legislature. On Jan. 1st, 2020 the bill will prohibit the sale of animal-tested cosmetics in the state. The European Union ended importation Read more…
Since 2 years, we saw AI (Artificial Intelligence) spreading in more and more domains, sometime presented as the “panacée” of all problems. In healthcare, and especially in drug discovery, many announces are done but, to Read more…
1 Comment
SLAS Washington 2019: the evidence of 3D culture for drug discovery! | HCS Pharma · February 14, 2019 at 1:57 pm
[…] BIOMIMESYS® technology in a talk during the tutorial organized by Molecular Devices (see our poster here – if you want the presentation, please contact […]